Reply to Yılmaz et al, “Caution in interpreting tralokinumab outcomes in dupilumab nonresponders”
Authors:
- Vikash OzaVOVikash Oza
- Theodora K. KaragounisTKTheodora K. Karagounis
- 6 August 2026
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
Abstract
No abstract availableFunding Information
- National Institutes of Health
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K 08AR084045)
This publication has 1 reference indexed in Scilit:
- Tralokinumab as an effective alternative after dupilumab treatment failure in moderate-to-severe atopic dermatitis: A real-world studyJournal of the American Academy of Dermatology, 2024